# Ruijin Hospital: Phase 4 study in Atrial Fibrillation (Persistent), Catheter Ablation (472 participants)

**Score:** 65/100

| Field | Value |
|---|---|
| Sponsor | Ruijin Hospital |
| Sponsor type | Academic and hospital |
| Study | An Investigator-initiated, Prospective, Open-label, Multicenter Randomized Controlled Trial, Comparing the Efficacy of Sacubitril/Valsartan and Standard Treatment on Atrial Fibrillation Recurrence After Catheter Ablation in Persistent Atrial Fibrillation Patients Without Hypertensive |
| NCT ID | NCT07910058 |
| Phase | Phase 4 |
| Status | not yet recruiting |
| Conditions | Atrial Fibrillation (Persistent); Catheter Ablation; Non-hypertension; Angiotensin Receptor/Neprilysin Inhibitor |
| Intervention types | drug, other |
| Target enrollment | 472 |
| Posted | 2026-11-02 |
| Planned start | 2026-10-31 |
| Event | Newly registered study |
| Event date | 2026-11-02 |

## Why this score
- Posted in the last two weeks.
- 472 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07910058). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.